Sutro Biopharma(STRO) Newsfilter·2025-03-15 22:40Core Insights - Sutro Biopharma, Inc. announced expanded data from the REFRαME-O1 trial for luveltamab tazevibulin (luvelta) in patients with platinum-resistant ovarian cancer, showcasing promising results at the SGO Annual Meeting [1][2] Group 1: Clinical Data and Results - Luvelta demonstrated encouraging antitumor activity in late-stage ovarian cancer patients with Folate Receptor-α (FRα) expression of 25% or greater, achieving an overall response rate (ORR) of 32% at the optimized dose of 5.2 mg/kg [2][9] - The disease control rate (DCR) at the 5.2 mg/kg dose was 96%, compared to an ORR of 13.8% and a DCR of 69% for the 4.3 mg/kg group [9] - Safety profiles were consistent across dosing groups, with no new safety signals observed and neutropenia well-managed [9] Group 2: Treatment Implications - The data suggests potential for improved patient responses compared to standard chemotherapy, particularly for patients with FRα expression between 25% and 75%, addressing an important unmet medical need [3] - The optimized dosing regimen selected was 5.2 mg/kg + G-CSF for two cycles, followed by 4.3 mg/kg [2] Group 3: Company Strategy and Future Directions - Despite the promising data, the company announced it is deprioritizing investment in the development of luvelta across all indications and is exploring out-licensing opportunities [5] - Luveltamab tazevibulin is designed to treat a broad range of ovarian cancer patients, including those with lower FRα expression, and has received Fast Track designation from the FDA for ovarian cancer [7]